Regular Consumption of Lipigo® Promotes the Reduction of Body Weight and Improves the Rebound Effect of Obese People Undergo a Comprehensive Weight Loss Program
Open accessAbstract
Obesity is a global public health problem. Objective: To evaluate the effect of the regular consumption of the product Lipigo® on body weight and rebound effect on overweight/obese subjects undergoing a comprehensive weight loss program. Methods: A randomized, parallel, double-blind, placebo-controlled clinical trial was conducted with male and female subjects presenting a BMI 25–39.9 kg/m2. All subjects underwent a comprehensive weight loss program (WLP) for 12 weeks, which included an individualized hypocaloric diet, physical activity recommendations, nutritional education seminars, and three times a day consumption of the product Lipigo® or Placebo. After-WLP, subjects continued the treatment for 9 months to assess rebound effect. Body weight (BW), BMI, and body composition were measured at the beginning and the end of the WLP, and in the follow-up. Results: A total of 120 subjects (85% women) 49.0 ± 9.5 years old and with a BW of 81.57 ± 13.26 kg (BMI 31.19 ± 3.44 kg/m2) were randomized and 73 subjects finished the study. At the end of the WLP, there was a tendency toward reduced BW (p = 0.093), BMI (p = 0.063), and WC (p = 0.059) in the treated group. However, subjects with obesity type 1 (OB1) from the treated group significantly reduced body weight (−5.27 ± 2.75 vs. −3.08 ± 1.73 kg; p = 0.017) and BMI (−1.99 ± 1.08 vs. −1.09 ± 0.55 kg/m2; p = 0.01) compared with placebo. They also presented a minor rebound effect after 9 months with product consumption (−4.19 ± 3.61 vs. −1.44 ± 2.51 kg; p = 0.026), minor BMI (−1.61 ± 1.43 vs. −0.52 ± 0.96 kg/m2; p = 0.025) and tended to have less fat-mass (−3.44 ± 2.46 vs. −1.44 ± 3.29 kg; p = 0.080) compared with placebo. Conclusions: The regular consumption of the product Lipigo® promotes the reduction of body weight and reduces the rebound effect of obese people after 52 weeks (12 months), mainly in obesity type 1, who undergo a comprehensive weight loss program.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Natural or complementary products such as berberine, silibnin, and Lipigo have been studied for weight loss, with reported side effects ranging from bloating and flatulence to more clinically significant GI disturbances.
“Additionally, some natural or complementary products, such as berberine, silibnin, and Lipigo, have been studied for weight loss, with reported side effects ranging from bloating and flatulence to more clinically significant GI disturbances [14,17].”
From Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review (2025) · cites this paper as [17]
Lipigo, Gymnema sylvestre, berberine, obex, and vutiglabridin demonstrated favorable short-term tolerability with only mild, transient GI events.
“Agents such as Lipigo, Gymnema sylvestre, berberine, obex, and vutiglabridin demonstrated favorable short-term tolerability with only mild, transient GI events [14,15,17,19].”
From Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review (2025) · cites this paper as [17]
In Valero-Pérez et al., bloating occurred in 24.3% versus 2.9% with placebo at week 2.
“In Valero-Pérez et al., bloating occurred in 24.3% vs. 2.9% placebo at week 2, with no other significant GI differences and no withdrawals due to GI events [17].”
From Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review (2025) · cites this paper as [17]
Natural and emerging compounds such as silibinin, Lipigo, Gymnema sylvestre, berberine, and vutiglabridin appear well tolerated in early studies.
“Natural and emerging compounds such as silibinin, Lipigo, Gymnema sylvestre, berberine, and vutiglabridin appear well tolerated in early studies, but their small sample sizes and short follow-up preclude strong conclusions [14,15,17,22].”
From Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review (2025) · cites this paper as [17]
The small sample sizes and short follow-up of studies of natural and emerging compounds preclude strong conclusions.
“Natural and emerging compounds such as silibinin, Lipigo, Gymnema sylvestre, berberine, and vutiglabridin appear well tolerated in early studies, but their small sample sizes and short follow-up preclude strong conclusions [14,15,17,22].”
From Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review (2025) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918 · see citing works
Finucane, M. M., Stevens, G. A., Cowan, M. J., Danaei, G., Lin, J. K., Paciorek, C. J., Singh, G. M., Gutierrez, H. R., Lu, Y., Bahalim, A. N., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62037-5 · Cited by 4,050 · see citing works
Bioelectrical impedance analysis—part II: utilization in clinical practice
Kyle, U. G., Bosaeus, I., De Lorenzo, A. D., Deurenberg, P., Elia, M., Manuel Gómez, J., Lilienthal Heitmann, B., Kent-Smith, L., Melchior, J.-C., Pirlich, M., et al. (2004) · Clinical Nutrition · doi:10.1016/j.clnu.2004.09.012 · Cited by 2,350 · see citing works
Obesity and the metabolic syndrome in developing countries.
Misra, A., & Khurana, L. (2008) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2008-1595 · Cited by 1,332 · see citing works
Dombrowski, S. U., Knittle, K., Avenell, A., Araujo-Soares, V., & Sniehotta, F. F. (2014) · BMJ · doi:10.1136/bmj.g2646 · Cited by 816 · see citing works
Sun, S. S., Chumlea, W. C., Heymsfield, S. B., Lukaski, H. C., Schoeller, D., Friedl, K., Kuczmarski, R. J., Flegal, K. M., Johnson, C. L., & Hubbard, V. S. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.2.331 · Cited by 701 · see citing works
Wycherley, T. P., Moran, L. J., Clifton, P. M., Noakes, M., & Brinkworth, G. D. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.044321 · Cited by 606 · see citing works
Beta Glucan: Health Benefits in Obesity and Metabolic Syndrome
Khoury, D. T. D. E., Cuda, C., Luhovyy, B. L., & Anderson, G. H. (2011) · Journal of Nutrition and Metabolism · doi:10.1155/2012/851362 · Cited by 548 · see citing works
Is bioelectrical impedance accurate for use in large epidemiological studies?
Dehghan, M., & Merchant, A. T. (2008) · Nutrition Journal · doi:10.1186/1475-2891-7-26 · Cited by 506 · see citing works
Duncan, D. T., Wolin, K. Y., Scharoun-Lee, M., Ding, E. L., Warner, E. T., & Bennett, G. G. (2011) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/1479-5868-8-20 · Cited by 353 · see citing works
Epidemiology of Obesity in Adults: Latest Trends
Inoue, Y., Qin, B., Poti, J., Sokol, R., & Gordon-Larsen, P. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0317-8 · Cited by 308 · see citing works
Loveman, E., Frampton, G., Shepherd, J., Picot, J., Cooper, K., Bryant, J., Welch, K., & Clegg, A. (2011) · Health Technology Assessment · doi:10.3310/hta15020 · Cited by 296 · see citing works
Puri, K., Suresh, K., Gogtay, N., & Thatte, U. (2009) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.52846 · Cited by 296 · see citing works
Hooper, L., Abdelhamid, A., Moore, H., Douthwaite, W., Skeaff, C., & Summerbell, C. (2012) · British medical journal · doi:10.1136/bmj.e7666 · Cited by 289 · see citing works
Immune-modulatory effects of dietary Yeast Beta-1,3/1,6-D-glucan
Stier, H., Ebbeskotte, V., & Gruenwald, J. (2014) · Nutrition Journal · doi:10.1186/1475-2891-13-38 · Cited by 266 · see citing works
Exposing the exposures responsible for type 2 diabetes and obesity
Franks, P. W., & McCarthy, M. I. (2016) · Science · doi:10.1126/science.aaf5094 · Cited by 265 · see citing works
Johansson, K., Neovius, M., & Hemmingsson, E. (2014) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.070052 · Cited by 243 · see citing works
Obesity and cancer pathogenesis
Berger, N. A. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12416 · Cited by 231 · see citing works
Randomized, double-blind trial of chitosan for body weight reduction
Pittler, M., Abbot, N. C., Harkness, E. F., & Ernst, E. (1999) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1600733 · Cited by 156 · see citing works
Mhurchú, C. N., Poppitt, S. D., McGill, A., Leahy, F. E., Bennett, D., Lin, R., Ormrod, D. J., Ward, L. C., Strik, C., & Rodgers, A. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802693 · Cited by 149 · see citing works
Plasma lipid changes after supplementation with β-glucan fiber from yeast
Nicolosi, R. J., Bell, S. J., Bistrian, B. R., Greenberg, I., Forse, R. A., & Blackburn, G. L. (1999) · American Journal of Clinical Nutrition · doi:10.1093/ajcn.70.2.208 · Cited by 142 · see citing works
Freimund, S., Sauter, M., Käppeli, O., & Dutler, H. (2003) · Carbohydrate Polymers · doi:10.1016/s0144-8617(03)00162-0 · Cited by 140 · see citing works
Evaluating Efficacy of a Chitosan Product Using a Double-Blinded, Placebo-Controlled Protocol
Kaats, G. R., Michalek, J. E., & Preuss, H. G. (2006) · Journal of the American College of Nutrition · doi:10.1080/07315724.2006.10719550 · Cited by 85 · see citing works
Single-blind, placebo controlled randomised clinical study of chitosan for body weight reduction
Trivedi, V., Satia, M., Deschamps, A., et al. (2015) · Nutrition Journal · doi:10.1186/s12937-016-0122-8 · Cited by 67 · see citing works
Impact of weight regain on metabolic disease risk: a review of human trials.
Kroeger, C. M., Hoddy, K. K., & Varady, K. A. (2014) · Journal of Obesity · doi:10.1155/2014/614519 · Cited by 55 · see citing works
Woodgate, D., & Conquer, J. A. (2003) · Current Therapeutic Research · doi:10.1016/s0011-393x(03)00058-4 · Cited by 54 · see citing works
Nutraceutical Supplements for Weight Loss
Poddar, K. H., Kolge, S., Bezman, L., Mullin, G. E., & Cheskin, L. J. (2011) · Nutrition in Clinical Practice · doi:10.1177/0884533611419859 · Cited by 49 · see citing works
Moraru, C., Mincea, M. M., Frandeș, M., Timar, B., & Ostafe, V. (2018) · Medicina · doi:10.3390/medicina54060109 · Cited by 47 · see citing works
Yeast hydrolysate can reduce body weight and abdominal fat accumulation in obese adults
Jung, E. Y., Cho, M. K., Hong, Y.-H., et al. (2013) · Nutrition · doi:10.1016/j.nut.2013.02.009 · Cited by 34 · see citing works
Yanni, A. E., Stamataki, N. S., Konstantopoulos, P. S., Stoupaki, M. G., Abeliatis, A., Nikolakea, I., Perrea, D. N., Karathanos, V. Τ., & Tentolouris, N. (2016) · European Journal of Nutrition · doi:10.1007/s00394-016-1315-9 · Cited by 31 · see citing works
Pokhis, K., Bitterlich, N., Cornelli, U., & Cassano, G. (2015) · BMC Obesity · doi:10.1186/s40608-015-0053-5 · Cited by 25 · see citing works
Santas, J., Lázaro, E., & Cuñé, J. (2017) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.8301 · Cited by 21 · see citing works
Cornelli, U., Belcaro, G. V., Recchia, M., & D’Orazio, N. (2017) · Current Developments in Nutrition · doi:10.3945/cdn.117.000919 · Cited by 19 · see citing works
Methodology of nutritional surveillance. Report of a Joint FAO/UNICEF/WHO Expert Committee.
(1976) · PubMed · Cited by 19 · see citing works
Cornelli, U., Belcaro, G. V., Cesarone, M. R., et al. (2008) · PubMed · Cited by 16 · see citing works
Rashad, N. M., Sayed, S. E., Sherif, M. H., & Sitohy, M. Z. (2019) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2019.05.027 · Cited by 15 · see citing works
The association between discrepant weight perceptions and objectively measured physical activity
Coleman, L., & Loprinzi, P. D. (2016) · Preventive Medicine · doi:10.1016/j.ypmed.2016.02.004 · Cited by 6 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Takrori, E., Peshin, S., & Singal, S. (2025) · Medicina · doi:10.3390/medicina61111987 · Cited by 13 · see citing works
- Authors
- Valero-Pérez, M., Bermejo, L. M., López-Plaza, B., García, M. A., Palma-Milla, S., & Gómez-Candela, C.
- Affiliations
- Nutrition Research Group, Hospital La Paz Institute for Health Research (IdiPAZ), 2804 Madrid, Spain
- Universidad Complutense de Madrid (ES)
- AB-BIOTICS SA, Av. Torre Blanca 57, 08172 Sant Cugat del Valles, Spain
- Nutrition Department, La Paz University Hospital, Nutrition Research Group, Hospital La Paz Institute for Health Research (IdiPAZ), Autonomous University of Madrid, 28046 Madrid, Spain
- Corresponding author
- Bermejo, Laura M.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2020-06-30
- Volume
- 12
- Issue
- 7
- Pages
- 1960
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC7399819
- OpenAlex
- W3040241064
- Cited by
- 10
- References
- 37
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 3
- FWCI
- 0.45
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Hispana (submittedVersion)
- Biblos-e Archivo (Universidad Autónoma de Madrid) (submittedVersion, public-domain)
- Funders
- Ministerio de Economía, Industria y Competitividad, Gobierno de España (RTC-2016-5317-1)
- Topics
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- simple obesity, weight loss, rebound effect, dietary supplements, hypocaloric diet, physical activity, body composition, waist circumference, body mass index, overweight, fat mass, fat-free mass, weight regain prevention, nutrition education, dietary adherence
- MeSH terms
- Adult, Body Composition, Body Weight, Diet, Reducing, Double-Blind Method, Female, Humans, Male, Middle Aged, Obesity, Weight Loss, Exercise, Body Mass Index, Treatment Outcome, Anti-Obesity Agents, Dietary Supplements, Weight Reduction Programs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
